Fimasartan, a novel angiotensin II receptor antagonist

[1]  Ji Han Kim,et al.  Synthesis and Antihypertensive Activity of Pyrimidin‐4(3H)‐one Derivatives as Losartan Analogue for New Angiotensin II Receptor Type 1 (AT1) Antagonists. , 2012 .

[2]  K. Seung,et al.  Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies. , 2012, Clinical therapeutics.

[3]  M. Volpe,et al.  New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil , 2012, Integrated Blood Pressure Control.

[4]  Hae-Young Lee,et al.  Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients , 2012, Clinical therapeutics.

[5]  Ji Han Kim,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[6]  M. Burnier,et al.  Angiotensin II Type 1 Receptor Blockers , 2001, Circulation.

[7]  T. Ogihara,et al.  [Angiotensin II type 1 receptor gene]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[8]  R. Alexander,et al.  Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. , 1998, Hypertension.

[9]  S. Wood,et al.  Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. , 1987, British medical journal.

[10]  M. Antonaccio,et al.  Enzyme inhibitors of the renin-angiotensin system. , 1987, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.